NovaBay Pharmaceuticals Croissance future
Future contrôle des critères 0/6
NovaBay Pharmaceuticals is forecast to grow earnings and revenue by 70.5% and 7.7% per annum respectively while EPS is expected to grow by 130.4% per annum.
Informations clés
70.5%
Taux de croissance des bénéfices
130.4%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 23.7% |
| Taux de croissance des recettes | 7.7% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 30 Aug 2024 |
Mises à jour récentes de la croissance future
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -3 | N/A | 0 | 1 |
| 12/31/2025 | 14 | -4 | N/A | -3 | 2 |
| 12/31/2024 | 11 | -6 | N/A | -4 | 2 |
| 6/30/2024 | 14 | -17 | -3 | -3 | N/A |
| 3/31/2024 | 15 | -19 | -4 | -4 | N/A |
| 12/31/2023 | 15 | -17 | -4 | -4 | N/A |
| 9/30/2023 | 13 | -15 | -5 | -5 | N/A |
| 6/30/2023 | 13 | -19 | -6 | -6 | N/A |
| 3/31/2023 | 13 | -17 | -6 | -6 | N/A |
| 12/31/2022 | 14 | -16 | -7 | -7 | N/A |
| 9/30/2022 | 14 | -9 | -10 | -10 | N/A |
| 6/30/2022 | 13 | -5 | -10 | -10 | N/A |
| 3/31/2022 | 12 | -5 | -10 | -10 | N/A |
| 12/31/2021 | 10 | -7 | -9 | -9 | N/A |
| 9/30/2021 | 9 | -7 | -6 | -6 | N/A |
| 6/30/2021 | 8 | -8 | -6 | -6 | N/A |
| 3/31/2021 | 10 | -11 | -5 | -5 | N/A |
| 12/31/2020 | 10 | -11 | -5 | -5 | N/A |
| 9/30/2020 | 10 | -13 | -5 | -5 | N/A |
| 6/30/2020 | 9 | -10 | -5 | -5 | N/A |
| 3/31/2020 | 7 | -8 | -6 | -6 | N/A |
| 12/31/2019 | 7 | -10 | -8 | -8 | N/A |
| 9/30/2019 | 8 | -8 | -9 | -8 | N/A |
| 6/30/2019 | 10 | -10 | -9 | -9 | N/A |
| 3/31/2019 | 11 | -9 | -8 | -8 | N/A |
| 12/31/2018 | 13 | -7 | -6 | -6 | N/A |
| 9/30/2018 | 15 | -4 | -7 | -7 | N/A |
| 6/30/2018 | 16 | -5 | -5 | -5 | N/A |
| 3/31/2018 | 17 | -6 | N/A | -5 | N/A |
| 12/31/2017 | 18 | -7 | N/A | -6 | N/A |
| 9/30/2017 | 16 | -10 | N/A | -4 | N/A |
| 6/30/2017 | 15 | -11 | N/A | -8 | N/A |
| 3/31/2017 | 14 | -12 | N/A | -9 | N/A |
| 12/31/2016 | 12 | -13 | N/A | -12 | N/A |
| 9/30/2016 | 9 | -16 | N/A | -16 | N/A |
| 6/30/2016 | 7 | -17 | N/A | -16 | N/A |
| 3/31/2016 | 6 | -19 | N/A | -19 | N/A |
| 12/31/2015 | 4 | -19 | N/A | -19 | N/A |
| 9/30/2015 | 3 | -19 | N/A | -18 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -17 | N/A |
| 3/31/2015 | 1 | -16 | N/A | -15 | N/A |
| 12/31/2014 | 1 | -15 | N/A | -15 | N/A |
| 9/30/2014 | 1 | -15 | N/A | -16 | N/A |
| 6/30/2014 | 2 | -14 | N/A | -15 | N/A |
| 3/31/2014 | 3 | -16 | N/A | -14 | N/A |
| 12/31/2013 | 3 | -16 | N/A | -13 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: NBY is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: NBY is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: NBY is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: NBY's revenue (7.7% per year) is forecast to grow slower than the US market (8.9% per year).
Croissance élevée des revenus: NBY's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if NBY's Return on Equity is forecast to be high in 3 years time